Accessibility Menu
Ascendis Pharma A/s logo

Ascendis Pharma A/s

(NASDAQ) ASND

Current Price$261.33
Market Cap$16.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+6%
5 Year+116%
1 Year+47%
1 Month+13%
Ascendis Pharma A/s last closing stock price
MetricPriceDate
Last closeUSD 261.002026-07-17
Ascendis Pharma A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.49%USD 270.452026-07-10
1 month+12.91%USD 231.152026-06-17
3 month+6.76%USD 244.482026-04-17
Year to date+22.4%USD 213.242025-12-31
1 year+47.29%USD 177.202025-07-17
3 year+193.26%USD 89.002023-07-18
5 year+115.63%USD 121.042021-07-16
Since inception+6.37%USD 245.382026-04-20

Ascendis Pharma A/s Financials at a Glance

Market Cap

$16.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€867.51M

Net Income (TTM)

€506.60M

EPS (TTM)

$8.87

P/E Ratio

27.77

Dividend

$0.00

Beta (Volatility)

0.74 (Low)

Price

$261.33

Volume

668,250.296

Open

$259.50

Previous Close

$261.00

Daily Range

$259.20 - $267.50

52-Week Range

$160.86 - $282.15

Estimated Earnings Date

Aug 6, 2026

ASND News

SellAlert-Blue.png

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma

Jonathan PoncianoMay 14, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ascendis Pharma A/s

Ascendis Pharma A/S is a biopharmaceutical company focused on developing innovative therapeutic solutions for critical medical conditions. The company is known for its flagship product, SKYTROFA, which addresses growth hormone deficiency (GHD) and has a promising pipeline of TransCon-branded candidates.

Products and Services
  • SKYTROFA, a treatment for growth hormone deficiency
  • TransCon Growth Hormone for pediatric and adult GHD patients
  • TransCon parathyroid hormone for hypoparathyroidism and TransCon CNP for achondroplasia
Growth Outlook
  • Strong pipeline with multiple candidates in various stages of development
  • Recent quarterly revenue growth indicates increasing market demand
  • Expansion into new markets, including Japan for pediatric GHD
Financial Highlights
  • Q1 2026 revenue of €250.66 million, up from €245.18 million in Q4 2025
  • Gross profit margin of 91.37% in Q1 2026, reflecting operational efficiency
  • Cash and cash equivalents of €573.42 million as of Q1 2026, providing financial stability
Ascendis Pharma A/S is positioned in the biotechnology sector, focusing on unmet medical needs. The company’s flagship product, SKYTROFA, has established a foothold in the market, while its diverse pipeline showcases a commitment to innovation. The recent revenue growth and high gross profit margins indicate a strong operational foundation, which may attract investor interest. With a solid cash position, Ascendis is well-equipped to navigate future challenges and capitalize on growth opportunities in the biopharmaceutical landscape.
AI Generated • Jun 21, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Jan Møller Mikkelsen

Website

www.ascendispharma.com

Headquarters

Hellerup, CR 2900, DK

ASND Financials

Key Financial Metrics (TTM)

Gross Margin

88.17%

Operating Margin

-0.80%

Net Income Margin

58.40%

Return on Equity

-5641.90%

Return on Capital

-18.47%

Return on Assets

25.26%

Earnings Yield

3.60%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$16.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

62.11M

Volume

668.25K

Avg. Volume

771.35K

Financials (TTM)

Gross Profit

€764.89M

Operating Income

-€6.93M

EBITDA

€12.37M

Operating Cash Flow

€57.63M

Capital Expenditure

-€15.53M

Free Cash Flow

€42.11M

Cash & ST Invst.

€573.42M

Total Debt

€897.60M

Ascendis Pharma A/s Performance Analysis

Ascendis Pharma A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 53,782,560485.0%
20232023-12-31EUR 288,352,991436.1%
20242024-12-31EUR 393,347,10836.4%
20252025-12-31EUR 812,725,097106.6%
Ascendis Pharma A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3056.6%
Q32025-09-3035.2%
Q42025-12-3114.8%
Q12026-03-312.2%
Ascendis Pharma A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -10.9332.1%
20232023-12-31EUR -9.25-15.4%
20242024-12-31EUR -7.06-23.6%
20252025-12-31EUR -4.25-39.9%
Ascendis Pharma A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3048.1%
Q32025-09-30-22.0%
Q42025-12-3146.0%
Q12026-03-311935.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

€250.66M

+148.3%

Gross Profit

€229.03M

+174.5%

Gross Margin

91.37%

N/A

Market Cap

$16.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$15.94M

N/A

Employees

1,017

N/A

Net Income

€639.69M

+776.0%

EBITDA

€23.68M

+153.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

€573.42M

+10.7%

Total Debt

€897.60M

+5.9%

Accounts Receivable

€196.81M

+195.1%

Inventory

€314.67M

+7.4%

Long Term Debt

€386.51M

+8.2%

Short Term Debt

€511.09M

+4.3%

Return on Assets

25.26%

N/A

Return on Invested Capital

-0.79%

N/A

Free Cash Flow

-€15.69M

-4.5%

Operating Cash Flow

-€7.85M

+45.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BBIOBridgeBio Pharma, Inc.
$81.38+1.34%
EXELExelixis, Inc.
$55.92+0.43%
MDGLMadrigal Pharmaceuticals, Inc.
$553.48+1.46%
GHGuardant Health, Inc.
$155.87+0.56%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NFLXNetflix
$68.95-0.07%
INTCIntel
$95.04-0.02%

Questions About ASND

What is the current price of Ascendis Pharma A/s?

Ascendis Pharma A/s is trading at $261.00 per share.

What is the 52-week range for Ascendis Pharma A/s?

Over the past 52 weeks, Ascendis Pharma A/s has traded between $160.86 and $282.15.

How much debt does Ascendis Pharma A/s have?

As of the most recent reporting period, Ascendis Pharma A/s reported total debt of €1.03B.

How much cash does Ascendis Pharma A/s have on hand?

Ascendis Pharma A/s reported €660.00M in cash and cash equivalents in its most recent financial results.

What is Ascendis Pharma A/s’s dividend yield?

Ascendis Pharma A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services